Target : Transfer of Serca2a gene AAV1 vector type (adeno-associated virus 1) for treating severe heart failure. Trial Phase 2, double blind, multicenter, on 44 HIV-negative AAV1 patients. 22 patients randomized toAAV1-CMV-Serca2a and 22 patients to an injection of physiologic serum, administered in both groups by slow intra-coronary infusion. All patients under optimal medical treatment. Stratified randomization on ischemic / non ischemic etiology.

Trial date : 2015

Number of patients : 44

Source of funding : Public (APHP) et private (ACTION Group & Celladon)

Centers participating : 5 french centers

N°NCT : NCT01966887

STATUT

To be published